Studying of Synergic Action of 1-β-D-Arabinofuranosylcytosine and Radionuclide Therapy with [131I]I-Labeled Methylene Blue on Surviving of B16F10 Melanoma Cells

The study aims to investigate methods for sensitizing malignant tumors to radiation therapy using [131I]I-labeled methylene blue in combination with DNA damage repair inhibitors. Studies showed that [131I]I-labeled methylene blue (with/without AraC) rapidly entered cells, with ~70% internalized within 3 h. Uptake decreased with a half-life of 3.5 days. Geant4 simulations calculated absorbed doses, revealing that the [131I]I-labeled methylene blue + AraC pair had an RBE of 5.13. Our findings indicate that in the presence of 1-β-D-arabinofuranosylcytosine (AraC), the survival fraction of irradiated B16F10 melanoma cells treated with iodine-131 is significantly reduced. This effect can be attributed to a decrease in cell proliferation in the overall population, as well as a reduction in the number of cancer stem cells specifically in the “AraC + I-131” group. These results hold promise for enhancing the efficacy of radionuclide therapy in the future.